Cutaneous adverse reaction to infliximab: Report of psoriasis developing in 3 patients

Cutis

Volumn 80, Issue 3, 2007, Pages 231-237

  Severs, Gregg A ^a,b   Lawlor, Tara H ^a   Purcell, Stephen M ^a   Adler, Donald J ^a   Thompson, Robert ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35348914628     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54-57.
2. Remicade [package insert]. Malvern, Pa: Centocor, Inc; 2005.
3. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48: 829-835.
4. Kipnis CD, Myers WA, Opeola M, et al. Biologic treatments for psoriasis. J Am Acad Dermatol. 2005;52: 671-682.
5. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49:112-117.
6. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542.
7. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-1847.
8. Oh C, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor-a (TNF-a) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42: 829-830.
9. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829-834.
10. Thurber M, Feasel A, Stroehlein J, et al. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439-440.
11. Dereure O, Guillot B, Jorgensen C, et al. Psoriatic lesions induced by antitumour necrosis factor-a treatment: two cases. Br J Dermatol. 2004;151:506-507.
12. Kary S, Worm M, Fritz J, et al. New onset or aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNFa antagonists: report of 8 cases [abstract]. Ann Rheum Dis. 2004;63(suppl):276.
13. Haibel H, Rudwaleit M, Strasser C, et al. Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNFa blocking agents [abstract]. Ann Rheum Dis. 2004;63(suppl):405.
14. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al [letter]. Arthritis Rheum, 2005;52:1333-1334.
15. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52: 2513-2518.
16. Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138: 1258-1259.
17. Beuthien W, Mellinghoff HU, Loske K, et al. Reply: unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum. 2005;52:1334.
18. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-821.
19. Strober BE. Experience with TNF inhibitors in psoriasis and psoriatic arthritis [report]. Psoriatic Disease Express Report. April 1, 2005. Available at: http://www.millennium-cme.com/reports/530-894-02-05-ER-Rpt.pdf. Accessed August 15, 2007.